{"id":"NCT02801370","sponsor":"Otonomy, Inc.","briefTitle":"Phase 3 Study of OTO-201 in Acute Otitis Externa","officialTitle":"A Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, Phase 3 Study of OTO-201 Given as a Single Administration for Treatment of Acute Otitis Externa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06","primaryCompletion":"2016-11","completion":"2016-12","firstPosted":"2016-06-15","resultsPosted":"2020-09-22","lastUpdate":"2020-10-19"},"enrollment":262,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Otitis Externa","Swimmer's Ear"],"interventions":[{"type":"DRUG","name":"12 mg ciprofloxacin","otherNames":["OTIPRIO"]},{"type":"DRUG","name":"Sham Control","otherNames":[]}],"arms":[{"label":"OTO-201","type":"EXPERIMENTAL"},{"label":"Control","type":"SHAM_COMPARATOR"}],"summary":"This is a prospective, randomized, double-blind, sham-controlled, multicenter, Phase 3 study in which eligible subjects with acute otitis externa (AOE) will be randomized to receive a single administration of either 12 mg OTO-201 or Sham-Control (empty syringe) to the external auditory canal of the affected ear(s).","primaryOutcome":{"measure":"Number of Subjects Considered a Clinical Cure at Day 8","timeFrame":"At Day 8 (1 week after dosing)","effectByArm":[{"arm":"12 mg OTO-201","deltaMin":91,"sd":null},{"arm":"Control","deltaMin":63,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":2,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":127},"commonTop":["Otitis externa","Ear Pain","Ear pruritis","Headache","Erythema"]}}